Analyst: Zegalogue launch should be "plug and play" for Novo Nordisk
![Novo Nordisk has purchased the rights to Zealand Pharma's rescue pen, Zegalogue | Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14383092.ece/ALTERNATES/schema-16_9/doc7mn4zc9obafxgql4kvz.jpg)
The sales and marketing muscles behind rescue pen Zegalogue (dasiclugon) will be beefed up by Novo Nordisk taking over the global marketing rights from Zealand Pharma, assesses Sydbank analyst Søren Løntoft Hansen.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk licenses hypoglycemia drug from Zealand Pharma
For subscribers